Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and MASCT in Advanced Solid Tumors
NCT02844881Phase 2Unknown
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Jul 2016
- Primary completion
- Jul 2018
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and MASCT-1 in solid tumor (advanced stage), sponsored by First People's Hospital of Lianyungang City. Primary endpoint: Incidence of treatment-related adverse events up to 2 years. Status: unknown.
02
Drugs
RivoceranibMASCT-1
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02844881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844881.